Written question asked by Kerry McCarthy (Labour) on Friday, 28 August 2020, in the House of Commons. It was due for an answer on Thursday, 3 September 2020 (named day). A holding answer was provided on Thursday, 3 September 2020. A substantive answer was provided by Jo Churchill (Conservative) on Monday, 14 September 2020 on behalf of the Department of Health and Social Care.
Spinal Muscular Atrophy: Nusinersen
- Question
-
To ask the Secretary of State for Health and Social Care, when NICE plans to undertake its review of evidence on the potential benefits of Spinraza for Type III spinal muscular atrophy patients who are not included in the managed access agreement between NHS England and Biogen.
- Answer
-
The National Institute for Health and Care Excellence (NICE) has committed to reviewing new evidence that becomes available on the benefits of Spinraza for non-ambulant SMA Type 3 patients, during the five-year course of the managed access agreement (MAA).
This review, involving patient groups, clinicians, the company and NHS England and NHS Improvement, will assess whether any new evidence has become available to support a change in the MAA treatment eligibility criteria. NICE and Biogen, the manufacturer of Spinraza, are preparing to initiate this evidence review as intended, once the company has sufficient data to make a submission to NICE.
Secondary information
- Type
- Written question
- Reference
- 81625
- Session
- 2019-21
- Subjects
- Spinal muscular atrophy Nusinersen
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2020-09-14 21:01:15 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2019-21/81625
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2019-21/81625
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2019-21/81625